Biomedix owns 75% of Meytav Technological Enterprises Innovation Center.
Biomedix Incubator Ltd. (TASE:BMDX) today raised NIS 6.6 million in a private placement. The participants in the placement were former Amgen VP Efi Cohen-Arazi, Delta Galil Industries chairman, president and CEO Dov Lautman, Meitav Investment and Securities Advisers Ltd. and Poalim IBI Underwriting and Investments Ltd. (TASE:PIU).
Biomedix owns 75% of Meytav Technological Enterprises Innovation Center Ltd. and is run by Pontifax partners Ran Nusbaum and managing partner Tomer Kariv. Pantifax is owned by Teva chairman Eli Hurvitz. Pontifax has a controlling shareholders agreement in Biomedix with Ituran co-CEO Eyal Sheratzky and Zeev Bronfeld.
Biomedix plans to use proceeds from the placement to make further investments in Israeli life sciences companies. In its notice to the Tel Aviv Stock Exchange (TASE), the company said it would continue providing financial and strategic support for its portfolio companies in order to add substantial value for the company’s shareholders. Meytav has over 20 life sciences, biotechnology, medical devices, immunization and imaging portfolio companies.
Published by Globes [online], Israel business news - www.globes.co.il - on October 15, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006